Category: adagrasib

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer

Shots: The companies collaborated to evaluate Mirati’s adagrasib (KRASG12C inhibitor) + Sanofi’s SAR442720 (SHP2 inhibitor) in P-I/II dose-escalation & expansion study in patients with previously-treated NSCLC & KRASG12C mutations Adagrasib & SAR442720 demonstrated an anti-tumor activity in pre-clinical models & both have complementary MoA Sanofi will be responsible for sponsoring & operating the P-I/II study & both […]

Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Shots: The P-I/II KRYSTAL–1 study evaluates adagrasib (600mg, bid) as monothx. and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation following prior systemic therapy The therapy showed the clinical activity and broad disease control. As of May 25 & July 9, 2021, 80% of patients received adagrasib mononthx. […]

QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer

Shots: The companies collaborated to develop a tissue based KRAS Cdx test to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, which is an investigational small molecule inhibitor of KRASG12 The agreement initially focuses on developing CDx for NSCLC and allows to further development of tests for […]